• Je něco špatně v tomto záznamu ?

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

M. Dolezel, M. Slavik, T. Blazek, T. Kazda, P. Koranda, L. Veverkova, P. Burkon, J. Cvek

. 2022 ; 12 (8) : . [pub] 20220729

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023639

Grantová podpora
NU22-03-00435, MMCI 00209805, FNOs/2022, CZ.02.1.01/0.0/0.0/16_019/0000868, SPP 911103671/31 Supported by the Ministry of Health of the Czech Republic, grant no. NU22-03-00435, and conceptual Development of Research Organization MMCI 00209805 and FNOs/2022. Supported by the European Regional Development Fund - Project ENOCH (No. CZ.02.1.01/0.0/0.

Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the "one dose fits all" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023639
003      
CZ-PrNML
005      
20221031095112.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm12081245 $2 doi
035    __
$a (PubMed)36013194
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dolezel, Martin $u Department of Oncology, Palacky University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
245    10
$a FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer / $c M. Dolezel, M. Slavik, T. Blazek, T. Kazda, P. Koranda, L. Veverkova, P. Burkon, J. Cvek
520    9_
$a Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the "one dose fits all" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Slavik, Marek $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 65652 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 0000000285915941
700    1_
$a Blazek, Tomas $u Department of Oncology, Faculty of Medicine, University Hospital Ostrava, 70852 Ostrava, Czech Republic $1 0000000184059568
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 65652 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 0000000172888975
700    1_
$a Koranda, Pavel $u Department of Nuclear Medicine, Palacky University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
700    1_
$a Veverkova, Lucia $u Department of Radiology, Palacky University Medical School & Teaching Hospital, 77900 Olomouc, Czech Republic
700    1_
$a Burkon, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 65652 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic $1 0000000298639376
700    1_
$a Cvek, Jakub $u Department of Oncology, Faculty of Medicine, University Hospital Ostrava, 70852 Ostrava, Czech Republic
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 12, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36013194 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095110 $b ABA008
999    __
$a ind $b bmc $g 1853956 $s 1174927
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 8 $e 20220729 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
GRA    __
$a NU22-03-00435, MMCI 00209805, FNOs/2022, CZ.02.1.01/0.0/0.0/16_019/0000868, SPP 911103671/31 $p Supported by the Ministry of Health of the Czech Republic, grant no. NU22-03-00435, and conceptual Development of Research Organization MMCI 00209805 and FNOs/2022. Supported by the European Regional Development Fund - Project ENOCH (No. CZ.02.1.01/0.0/0.
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Možnosti archivace